Udhayvir Grewal
@UGrewalMD
GI Oncologist @WinshipAtEmory via @uiowacancer #GIOnc#/#NETs#, clinical trials, cardiac disease in cancer ๐ฆ๐๏ธ@TheGutOncLab
665 Following 2K Followers
Thrilled to share this work, now out in @JournalCancer
Expert consensus statement on the use of incretin mimetics in patients with NENs, eloquently summarized by @OncoThor in the tweet below. Grateful to be a part of this effort. This statement not only provides guidance/expert advice on tackling this challenge in clinic when seeing patients but also highlights the need for robust prospective evidence to guide future use of these agents. @NANETS1 @ENETS_ORG @WinshipAtEmory
Show more
Authorsโ conclusion: The combination of FFX/bev plus atezo led to significantly longer PFS compared with atezo monotherapy in the first-line treatment of dMMR/MSI-H mCRC (which is misleading).
Correct conclusion: Atezolizumab led to inferior outcomes compared to FFX/bev plus atezo despite the well-established superiority of ICI over cytotoxic chemotherapy in MSI-H colorectal cancer, calling into question its role as the ICI of choice in this population.
Should this make you worried about ATOMIC? The answer should be 100%
My go-to for adjuvant therapy in MSI-H colon cancer is off-label PD-1 or on our clinical trial of toripalimab monotherapy led by my colleague Dr Emiloju @WinshipAtEmory
Show more
Happy to share our invited review on "Grade progression and high-grade transformation in Neuroendocrine Neoplasms" just out in @EndoCancer.
๐
Forever grateful to @IHC_guy for his mentorship on this and several other projects (crazy that I even know you and get to work with you). We hope that this will be a helpful guide for colleagues while dealing with this clinical challenge that I find to be incredibly hard to navigate. Thank you @NANETS1 for the nomination and co-authors @ChandrikhaC @PoHienEar @RaulSGonzalezMD @SethConcorsMD for your contribution to this work.
Show more
